Forecast

The analysts' average price target is +11,75€ (+51,81%). The median is +10,73€ (+38,63%).

Buy	14
Hold	19
Sell	4

News Go to news feed

Bluebird Mining Ventures Ltd schedules annual general meeting for 9 September in St Helier

Bluebird Mining Ventures Ltd has scheduled its annual general meeting for 9 September 2025 in St Helier, Jersey. The agenda includes the financial statements for the year ended 31 December 2024, reappointment of PKF Littlejohn as auditors, authorization to determine the auditors’ remuneration, re-election of Cedric Simonet and a proposal to approve share buybacks. Shareholders may appoint representatives; proxies must be submitted to Computershare Investor Services by 5 September 2025. The next audited financial statements will cover the period to 31 December 2025 and will be presented at the 2026 AGM. » More on de.investing.com
Kensington Trust Singapore reduces stake in Bluebird Mining Ventures below 5%

Kensington Trust Singapore Limited has reduced its stake in Bluebird Mining Ventures Ltd from 9.993% to 4.885%, falling below the reportable threshold of 5%. The reduction includes both directly held shares and financial instruments such as warrants. Bluebird Mining Ventures emphasizes its compliance with UK transparency guidelines and market abuse regulations. » More on de.investing.com
Bluebird Mining Ventures: major shareholders increase stake to 18.79%

Major shareholders RS & CA Jennings & Catalyse Capital Ltd have increased their stake in Bluebird Mining Ventures Ltd from 12.56% to 18.79%. The increase includes both direct voting rights and financial instruments such as spread-betting positions and warrants. Bluebird Mining Ventures reported the crossing of the notification threshold in accordance with UK disclosure rules. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2021, Bluebird Bio has already paid 7,69€ in dividends. The last payout was in November 2021.

Financials

In the last quarter, Bluebird Bio had revenue of 35.78m€ and net profit of −26.87m€

(EUR)	Mar 2025	YoY
Revenue	+35.78m	-
Gross profit	+24.47m	-
Net profit	−26.87m	-
EBITDA	−7.10m	-

Fundamentals

Metric	Value
Market capitalization	+41.78m€
Number of shares	9.79m
52-week high/low	+24,55€ - +2,75€
Dividends	No
Beta	0,37
P/E ratio	−0,20
PEG ratio	0,00
P/B ratio	−1,53
P/S ratio	+0,58

Company profile

bluebird bio, Inc. ist ein Biotechnologieunternehmen, das innovative Gentherapien für schwere genetische Krankheiten erforscht, entwickelt und vermarktet. Zu den Produktkandidaten des Unternehmens für schwere genetische Erkrankungen gehören Betibeglogene Autotemcel zur Behandlung der transfusionsabhängigen ß-Thalassämie, Lovotibeglogene Autotemcel zur Behandlung der Sichelzellkrankheit (SCD) und Elivaldogene Autotemcel zur Behandlung der zerebralen Adrenoleukodystrophie. Das klinische Studienprogramm des Unternehmens umfasst HGB-205, HGB-206 und HGB-210 zur Untersuchung der Sicherheit und Wirksamkeit von lovo-cel bei der Behandlung von Patienten mit SCD sowie HGB-204, HGB-205, HGB-207 und HGB-212 zur Untersuchung der Sicherheit und Wirksamkeit von beti-cel bei der Behandlung von Patienten mit ß-Thalassämie. Es hat strategische Kooperations- und Lizenzvereinbarungen mit Orchard Therapeutics Limited, Forty Seven, Inc. und Magenta Therapeutics, Inc. Das Unternehmen war früher unter dem Namen Genetix Pharmaceuticals, Inc. bekannt und änderte im September 2010 seinen Namen in bluebird bio, Inc. bluebird bio, Inc. wurde 1992 gegründet und hat seinen Hauptsitz in Cambridge, Massachusetts.

Name	Bluebird Bio
CEO	Andrew Obenshain
Headquarters	Cambridge, ma USA
Website	bluebirdbio.com
Sector	Health Care
Industry	Biotechnology
IPO	06/19/2013
Employees	248